Abstract
Purpose
Adiponectin possesses anti-inflammatory and insulin-sensitizing properties. Little is known about the role of adiponectin in hepatitis B-related liver disease.
Methods
Serum adiponectin and hepatitis B viral factors were cross-sectionally assayed in 280 patients with chronic hepatitis B virus (HBV) infection including 120 patients with chronic HBV infection, 40 patients with cirrhosis, and 120 patients with hepatocellular carcinoma (HCC); 116 healthy adults were used as controls. The dynamics of serum adiponectin level was also studied longitudinally in 25 patients with hepatitis B e antigen (HBeAg) seroconversion (SC).
Results
We found that serum adiponectin level in patients with chronic HBV infection was similar to that in healthy controls and was significantly lower than patients with cirrhosis and HCC. In univariate analysis, high serum adiponectin level significantly correlated with the presence of HBV-related cirrhosis or HCC, abnormal serum ALT level, and HBV genotype C. Multivariate analysis revealed that high serum adiponectin level significantly correlated with the development of HCC. Serum adiponectin levels remained stationary in patients experiencing HBeAg SC.
Conclusions
Our findings suggest that HBV infection itself does not affect adiponectin levels. Serum adiponectin level correlates with the progression of HBV-related liver diseases but not with the development of HBeAg SC.

Similar content being viewed by others
Explore related subjects
Discover the latest articles and news from researchers in related subjects, suggested using machine learning.References
Kao JH, Chen DS. Global control of hepatitis B virus. Lancet Infect Dis 2002;2:395–403. doi:10.1016/S1473-3099(02)00315-8
Lee WM. Hepatitis B virus infection. N Engl J Med 1997;337:1733–1745. doi:10.1056/NEJM199712113372406
Liu CJ, Chen PJ, Lai MY, Kao JH, Chang CF, Wu HL, et al. A prospective study characterizing full-length hepatitis B virus genomes during acute exacerbation. Gastroenterology 2003;124:80–90. doi:10.1053/gast.2003.50003
Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. The adipocyte-secreted protein ACRP30 enhances hepatic insulin action. Nat Med 2001;7:947–953. doi:10.1038/90992
Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999;257:79–83. doi:10.1006/bbrc.1999.0255
Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adipocyte-specific gene dysregulated in obesity. J Biol Chem 1996;271:10697–10703. doi:10.1074/jbc.271.18.10697
Hotta K, Funahashi T, Bodkin NL, Ortmeyer HK, Arita Y, Hansen BC, et al. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes 2001;50:1126–1133. doi:10.2337/diabetes.50.5.1126
Bajaj M, Suraamornkul S, Piper P, Hardies LJ, Glass L, Cersosimo E, et al. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. J Clin Endocrinol Metab 2004;89:200–206. doi:10.1210/jc.2003-031315
Gil-Campos M, Canete R, Gil A. Adiponectin, the missing link in insulin resistance and obesity. Clin Nutr 2004;23:963–974. doi:10.1016/j.clnu.2004.04.010
Masaki T, Chiba S, Tatsukawa H, Yasuda T, Noguchi H, Seike M, et al. Adiponectin protects LPS-induced liver injury through modulation of TNF-alfa in KK-Ay-obese mice. Hepatology 2004;40:177–184. doi:10.1002/hep.20282
Kamada Y, Tamura S, Kiso S, Matsumoto H, Saji Y, Yoshida Y, et al. Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology 2003;125:1796–1807. doi:10.1053/j.gastro.2003.08.029
Custro N, Carroccio A, Ganci A, Scafidi V, Campagna P, Di Prima L, et al. Glycemic homeostasis in chronic viral hepatitis and liver cirrhosis. Diabetes Metab 2001;27:476–481
Hui JM, Sud A, Farrell GC, Bandara P, Byth K, Kench JG, et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression. Gastroenterology 2003;125:1695–1704. doi:10.1053/j.gastro.2003.08.032
Jonsson JR, Moschen AR, Hickman IJ, Richardson MM, Kaser S, Clouston AD, et al. Adiponectin and its receptors in patients with chronic hepatitis C. J Hepatol 2005;43:929–936. doi:10.1016/j.jhep.2005.05.030
Kaser S, Moschen A, Cayon A, Kaser A, Crespo J, Pons-Romero F, et al. Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut 2005;54:117–121. doi:10.1136/gut.2003.037010
Liu CJ, Chen PJ, Jeng YM, Huang WL, Yang WS, Lai MY, et al. Serum adiponectin correlates with viral characteristics but not histologic features in patients with chronic hepatitis C. J Hepatol 2005;43:235–242. doi:10.1016/j.jhep.2005.02.044
Neumeier M, Hellerbrand C, Gäbele E, Buettner R, Bollheimer C, Weigert J, et al. Adiponectin and its receptors in rodent models of fatty liver disease and liver cirrhosis. World J Gastroenterol 2006;12:5490–5494
Petit JM, Minello A, Jooste V, Bour JB, Galland F, Duvillard L, et al. Decreased plasma adiponectin concentrations are closely related to steatosis in hepatitis C virus infected patients. J Clin Endocrinol Metab 2005;90:2240–2243. doi:10.1210/jc.2004-1266
Siagris D, Vafiadis G, Michalaki M, Lekkou A, Starakis I, Makri M, et al. Serum adiponectin in chronic hepatitis C and B. J Viral Hepat 2007;14:577–583. doi:10.1111/j.1365-2893.2007.00850.x
Tietge UJ, Boker KH, Manns MP, Bahr MJ. Elevated circulating adiponectin levels in liver cirrhosis are associated with reduced liver function and altered hepatic hemodynamics. Am J Physiol Endocrinol Metab 2004;287:E82–E92. doi:10.1152/ajpendo.00494.2003
Wang AY, Hickman IJ, Richards AA, Whitehead JP, Prins JB, Macdonald GA. High molecular weight adiponectin correlates with insulin sensitivity in patients with hepatitis C genotype 3 but not genotype 1 infection. Am J Gastroenterol 2005;100:2717–2723. doi:10.1111/j.1572-0241.2005.00311.x
Xu A, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper GJ. The fat-derived hormone adiponectin alleviates alcoholic and non-alcoholic fatty liver diseases in mice. J Clin Invest 2003;112:91–100
Yokoyama H, Hirose H, Ohgo H, Saito I. Inverse association between serum adiponectin level and transaminase activities in Japanese male workers. J Hepatol 2004;41:19–24. doi:10.1016/j.jhep.2004.03.003
Targher G, Bertolini L, Rodella S, Zoppini G, Scala L, Zenari L, et al. Associations between plasma adiponectin concentrations and liver histology in patients with non-alcoholic fatty liver disease. Clin Endocrinol (Oxf) 2006;64:679–683. doi:10.1111/j.1365-2265.2006.02527.x
Pagano C, Soardo G, Esposito W, Fallo F, Basan L, Donnini D, et al. Plasma adiponectin is decreased in non-alcoholic fatty liver disease. Eur J Endocrinol 2005;152:113–118. doi:10.1530/eje.1.01821
Musso G, Gambino R, Durazzo M, Biroli G, Carello M, Fagà E, et al. Adipokines in NASH: postprandial lipid metabolism as a link between adiponectin and liver disease. Hepatology 2005;42:1175–1183. doi:10.1002/hep.20896
Musso G, Gambino R, Biroli G, Carello M, Fagà E, Pacini G, et al. Hypoadiponectinemia predicts the severity of hepatic fibrosis and pancreatic beta-cell dysfunction in nondiabetic nonobese patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2005;100:2438–2446. doi:10.1111/j.1572-0241.2005.00297.x
Hui CK, Zhang HY, Lee NP, Chan W, Yueng YH, Leung KW, et al. Serum adiponectin is increased in advancing liver fibrosis and declines with reduction in fibrosis in chronic hepatitis B. J Hepatol 2007;47:191–202. doi:10.1016/j.jhep.2007.02.023
Kaser S, Moschen A, Kaser A, Ludwiczek O, Ebenbichler CF, Vogel W, et al. Circulating adiponectin reflects severity of liver disease but not insulin sensitivity in liver cirrhosis. J Intern Med 2005;258:274–280. doi:10.1111/j.1365-2796.2005.01543.x
Tacke F, Wüstefeld T, Horn R, Luedde T, Srinivas Rao A, Manns MP, et al. High adiponectin in chronic liver disease and cholestasis suggests biliary route of adiponectin excretion in vivo. J Hepatol 2005;42:666–673. doi:10.1016/j.jhep.2004.12.024
Lu JY, Chuang LM, Yang WS, Tai TY, Lai MY, Chen PJ, et al. Adiponectin levels among patients with chronic hepatitis B and C infections and in response to IFN-alpha therapy. Liver Int 2005;25:752–759. doi:10.1111/j.1478-3231.2005.1007.x
Hsu YS, Chien RN, Yeh CT, Sheen IS, Chiou HY, Chu CM, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002;35:1522–1527. doi:10.1053/jhep.2002.33638
Yeh SH, Tsai CY, Kao JH, Liu CJ, Kuo TJ, Lin MW, et al. Combined real-time PCR quantification and signature single nucleotide polymorphism genotyping of hepatitis B virus in one-tube reaction. J Hepatol 2004;41:659–666. doi:10.1016/j.jhep.2004.06.031
Tilg H, Wilmer A, Vogel W, Herold M, Nölchen B, Judmaier G, et al. Serum levels of cytokines in chronic liver diseases. Gastroenterology 1992;103:264–274
Acknowledgments
The study was supported by grants from the National Taiwan University Hospital; the National Taiwan University; the National Science Council (NSC 95-2314-B-002-094), Department of Health, Executive Yuan, Taiwan; National Health Research Institutes (NHRI-EX93-CD9201 and NHRI-EX94-CD9201), Taiwan; and Liver Disease Prevention and Treatment Research Foundation, Taiwan.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Liu, CJ., Chen, PJ., Lai, MY. et al. High serum adiponectin correlates with advanced liver disease in patients with chronic hepatitis B virus infection. Hepatol Int 3, 364–370 (2009). https://doi.org/10.1007/s12072-008-9111-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12072-008-9111-0
Keywords
Profiles
- Chen-Hua Liu View author profile